Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutics, which could be increased to $545.6 million. By leveraging Samsung Biologics’ robust expertise and […]

The post Samsung Biologics and AstraZeneca Forge Strategic Manufacturing partnership for global supply first appeared on World Pharma Today.



This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here

Share the post

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

×

Subscribe to Leading Pharmaceutical Industry Online Platform

Get updates delivered right to your inbox!

Thank you for your subscription

×